These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vaccines for prevention of meningococcal disease. Frasch CE Clin Microbiol Rev; 1989 Apr; 2 Suppl(Suppl):S134-8. PubMed ID: 2497956 [No Abstract] [Full Text] [Related]
3. Status of a group B Neisseria meningitidis vaccine. Frasch CE Eur J Clin Microbiol; 1985 Dec; 4(6):533-6. PubMed ID: 3937731 [No Abstract] [Full Text] [Related]
4. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development. Jennings HJ Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499 [No Abstract] [Full Text] [Related]
5. Vaccines against meningococcal meningitis: current status. Epidemiol Bull; 1994 Jul; 15(2):13-5. PubMed ID: 8086300 [No Abstract] [Full Text] [Related]
6. [Vaccines against Neisseria meningitidis]. Ferrón L; Criado MT; Ferreirós CM Enferm Infecc Microbiol Clin; 1992 May; 10(5):296-301. PubMed ID: 1391002 [No Abstract] [Full Text] [Related]
9. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Noronha CP; Struchiner CJ; Halloran ME Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439 [TBL] [Abstract][Full Text] [Related]
11. Current status of meningococcal group B vaccine candidates: capsular or noncapsular? Diaz Romero J; Outschoorn IM Clin Microbiol Rev; 1994 Oct; 7(4):559-75. PubMed ID: 7834605 [TBL] [Abstract][Full Text] [Related]
12. [Preventive effectiveness of an urgent mass vaccination with purified meningococcal polysaccharide vaccine observed during a meningitis epidemic]. Wu C Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Dec; 6(6):344-6. PubMed ID: 3938683 [No Abstract] [Full Text] [Related]
13. Microbiology. A furtive pathogen revealed. Nassif X Science; 2000 Mar; 287(5459):1767-8. PubMed ID: 10755929 [No Abstract] [Full Text] [Related]
14. Bacterial outer membrane protein vaccines. The meningococcal example. Poolman JT Adv Exp Med Biol; 1996; 397():73-7. PubMed ID: 8718585 [No Abstract] [Full Text] [Related]
15. Vaccine against meningococcal group B disease. Lifely MR; Moreno C Lancet; 1986 Jan; 1(8474):214-5. PubMed ID: 2868239 [No Abstract] [Full Text] [Related]
16. [The outer membrane proteins of Neisseria meningitidis: the outlook for their use in developing preparations for immunoprophylaxis]. Filatova TN Zh Mikrobiol Epidemiol Immunobiol; 1990 Feb; (2):86-95. PubMed ID: 2111623 [No Abstract] [Full Text] [Related]
17. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. Lepow ML; Beeler J; Randolph M; Samuelson JS; Hankins WA J Infect Dis; 1986 Dec; 154(6):1033-6. PubMed ID: 3097160 [No Abstract] [Full Text] [Related]
18. Transferrin receptors of Neisseria meningitidis: promising candidates for a broadly cross-protective vaccine. Ala'Aldeen DA J Med Microbiol; 1996 Apr; 44(4):237-43. PubMed ID: 8606350 [TBL] [Abstract][Full Text] [Related]
19. [An animal model for testing the activity of meningococcal polysaccharide vaccine]. Huet M; Suire A J Biol Stand; 1981 Jan; 9(1):67-74. PubMed ID: 6783665 [No Abstract] [Full Text] [Related]
20. Effect of Neisseria meningitidis group A polysaccharide vaccine on nasopharyngeal carrier rates. Sivonen A J Infect; 1981 Sep; 3(3):266-72. PubMed ID: 6821094 [No Abstract] [Full Text] [Related] [Next] [New Search]